Wheeler Bio And Charles River Laboratories Announce Agreement To Build And Operate RightSource Laboratory
Portfolio Pulse from Happy Mohamed
Wheeler Bio and Charles River Laboratories (NYSE:CRL) have announced an agreement to implement RightSource, an insourced, purpose-built lab, at Wheeler Bio's cGMP biologics manufacturing facility in Oklahoma City. The lab will be operational in Q3 2023 and is expected to start in-process and release testing by Q4 2023.
May 31, 2023 | 3:36 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Charles River Laboratories (NYSE:CRL) partners with Wheeler Bio to implement RightSource lab at Wheeler Bio's facility, expanding its reach and potentially increasing revenue.
The partnership between Charles River Laboratories and Wheeler Bio to implement the RightSource lab at Wheeler Bio's facility will expand Charles River's reach and make its quality control services more accessible to a broader range of companies. This could potentially lead to increased revenue for Charles River Laboratories in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100